These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 32571749)

  • 1. Significant histological changes and satisfying antiviral efficacy in chronic hepatitis B virus infection patients with normal alanine aminotransferase. Antiviral therapy decision in chronic HBV patients with normal ALT.
    Wu Z; Ma AL; Xie Q; Zhang XQ; Cheng J; Zhang DZ; Wang GQ; Zhao H
    Clin Res Hepatol Gastroenterol; 2021 Mar; 45(2):101463. PubMed ID: 32571749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical noninvasive markers for antiviral therapy decision in chronic hepatitis B with alanine aminotransferase less than two times upper limit of normal.
    Wu Z; Dong X; Wang G; Zhao H;
    J Viral Hepat; 2019 Feb; 26(2):287-296. PubMed ID: 30380162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of entecavir in chronic hepatitis B patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage.
    Wu IC; Lai CL; Han SH; Han KH; Gordon SC; Chao YC; Tan CK; Sievert W; Tanwandee T; Xu D; Neo BL; Chang TT
    Hepatology; 2010 Apr; 51(4):1185-9. PubMed ID: 20044806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is there a meaningful serum hepatitis B virus DNA cutoff level for therapeutic decisions in hepatitis B e antigen-negative chronic hepatitis B virus infection?
    Papatheodoridis GV; Manesis EK; Manolakopoulos S; Elefsiniotis IS; Goulis J; Giannousis J; Bilalis A; Kafiri G; Tzourmakliotis D; Archimandritis AJ
    Hepatology; 2008 Nov; 48(5):1451-9. PubMed ID: 18924246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical characteristics of hepatic flare and efficacy of antiviral therapy in pregnant women with chronic hepatitis B virus infection].
    Ding Y; Sheng QJ; Zhang C; Wu YY; Yuan SY; Xia TT; An ZY; Dou XG
    Zhonghua Gan Zang Bing Za Zhi; 2019 Feb; 27(2):106-111. PubMed ID: 30818914
    [No Abstract]   [Full Text] [Related]  

  • 6. Is it necessary to delay antiviral therapy for 3-6 months to anticipate HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B in endemic areas of HBV genotype C?
    Song BC; Cho YK; Jwa H; Choi EK; Kim HU; Song HJ; Na SY; Boo SJ; Jeong SU
    Clin Mol Hepatol; 2014 Dec; 20(4):355-60. PubMed ID: 25548741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of antiviral treatment in HBeAg-negative chronic hepatitis B patients with normal or mildly elevated alanine aminotransferase: a retrospective study.
    Wei S; Hu M; Chen H; Xie Q; Wang P; Li H; Peng J
    BMC Gastroenterol; 2022 Aug; 22(1):387. PubMed ID: 35978283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of individuals with chronic hepatitis B virus infection and persistent normal or mildly elevated aminotransferase levels.
    Yan JY; Li ZQ; Yu ZJ; Kan QC
    J Cell Biochem; 2019 Apr; 120(4):6632-6641. PubMed ID: 30368885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients.
    Zheng MH; Shi KQ; Dai ZJ; Ye C; Chen YP
    Clin Ther; 2010 Apr; 32(4):649-58. PubMed ID: 20435234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel nomogram to predict evident histological liver injury in patients with HBeAg-positive chronic hepatitis B virus infection.
    Chang X; Wang J; Chen Y; Long Q; Song L; Li Q; Liu H; Shang Q; Yu Z; Jiang L; Xiao G; Li L; Chen L; Wang X; Li Z; Chen D; Dong Z; An L; Tan L; Chen Y; Yang Y
    EBioMedicine; 2021 May; 67():103389. PubMed ID: 34004423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of liver histological changes and a sustained virological response to peginterferon among chronic hepatitis B e antigen-positive patients with normal or minimally elevated alanine aminotransferase levels.
    Chen J; Xu CR; Xi M; Hu WW; Tang ZH; Zang GQ
    J Viral Hepat; 2017 Jul; 24(7):573-579. PubMed ID: 28107601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-normal alanine aminotransferase is an indicator for liver histopathology in HBeAg-negative chronic hepatitis B.
    Duan M; Chi X; Xiao H; Liu X; Zhuang H
    Hepatol Int; 2021 Apr; 15(2):318-327. PubMed ID: 33638049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients.
    Sarin SK; Kumar M; Kumar R; Kazim SN; Guptan RC; Sakhuja P; Sharma BC
    Am J Gastroenterol; 2005 Nov; 100(11):2463-71. PubMed ID: 16279901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis B core antibody and liver stiffness measurements predict HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients with minimally elevated alanine aminotransferase (ALT) levels.
    Fu X; Lou H; Chen F; Gao X; Lin Z
    Clin Exp Med; 2020 May; 20(2):241-248. PubMed ID: 32052245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment efficacy of clevudine, entecavir and lamivudine in treatment-naive patients with HBeAg-positive chronic hepatitis B].
    Bae SH; Baek YH; Lee SW; Han SY
    Korean J Gastroenterol; 2010 Dec; 56(6):365-72. PubMed ID: 21173560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy.
    Li N; Xu JH; Yu M; Wang S; Si CW; Yu YY
    World J Gastroenterol; 2015 Nov; 21(43):12421-9. PubMed ID: 26604649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical efficacy of various antiviral-based strategies to treat chronic hepatitis patients with positivity for hepatitis B e antigen and rtN236T mutation].
    Yue W; Yuan H; Mao XR; Deng YD; Chen L
    Zhonghua Gan Zang Bing Za Zhi; 2013 Mar; 21(3):184-8. PubMed ID: 23967738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of treatment requirement in HBeAg-negative chronic hepatitis B patients with persistently normal alanine aminotransferase and high serum HBV DNA levels.
    Ormeci A; Aydın Y; Sumnu A; Baran B; Soyer OM; Pınarbasi B; Gokturk S; Gulluoglu M; Onel D; Badur S; Akyuz F; Karaca C; Demir K; Besisik F; Kaymakoglu S
    Int J Infect Dis; 2016 Nov; 52():68-73. PubMed ID: 27619844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of quantitative hepatitis B core antibody (qHBcAb) and aspartate aminotransferase (AST) can accurately diagnose immune tolerance of chronic hepatitis B virus infection based on liver biopsy.
    Chi Z; Zhao W; Li JW; Liu H; Shao C; Zhao H; Gui-Qiang W
    Clin Res Hepatol Gastroenterol; 2021 Nov; 45(6):101563. PubMed ID: 33272888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baseline Hepatitis B Virus DNA Level is a Promising Factor for Predicting the 3 (rd) Month Virological Response to Entecavir Therapy: A Study of Strict Defined Hepatitis B virus Induced Cirrhosis.
    Xu Y; Wu XN; Shi YW; Wei W; Yang AT; Sun YM; Zhao WS; You H
    Chin Med J (Engl); 2015 Jul; 128(14):1867-72. PubMed ID: 26168824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.